The population in the SURPASS clinical development program included a wide spectrum of people on the continuum of T2D—from participants treated with diet and exercise alone with a mean duration of diabetes of 4.7 years (SURPASS-1) to participants for whom basal insulin treatment was insufficient with a mean duration of diabetes of 13.3 years (SURPASS-5). This evidence concerns the gene INS and type 2 diabetes mellitus.